Drug Resistance in Breast and Ovarian Cancers

Dear Colleagues,

Recent breakthroughs in breast and ovarian cancers (BC, OC) highlight the growing need for molecular predictors paving the way for personalized care.

After the paradigm shift due to the advent of CDK 4/6 inhibitors and next-generation ER antagonists in ER+ BC, acquiring knowledge on acquired endocrine resistance is a major clinical challenge. The high prevalence of ESR1 gene mutations in anti-estrogen-treated metastatic disease underscores the “evolvability” of ER+ BC under the pressure of anti-oestrogen therapies. A better understanding of molecular processes underlying this evolution is needed. In the metastatic triple-negative BC (mTNBC) setting, preclinical research efforts on predictive biomarkers for Sacituzumab Govitecan efficacy in Trop-2-expressing mTNBC are growing; further insights into the underlying molecular hallmarks may help clarify multifaceted drug resistance.

Despite the latest advances in newly diagnosed OC, early relapse in patients due to chemoresistance poses a major clinical issue. Further investigation into putative biomarkers for drug resistance, including cancer stem cells, circulating tumor cells and miRNAs, is mandatory before their routine implementation.

This Special Issue focus on cellular and molecular hallmarks of endocrine resistance for ER+ MBC and drug resistance for ovarian cancer research. In this Special Issue, original research and review articles are welcome.

Dr. Tuula Kallunki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.